Table F-13

Surrogate outcome – TC:HDL-c ratio using fibrate plus statin therapy compared with statin monotherapy

Total cholesterol : High density lipoprotein cholesterol
TrialPopulationCombination Statin Dose (mg/day)Fibrate (mg/day)Combo NMonotherapy Statin Dose (mg/day)Mono NFollow-up (wk)Mean Baseline LDL-c (mg/dL)Combo-mono: mean difference (95% CI)AACJadad ScoreITTA
Combination – monotherapy: difference in mean percentage change from baseline
Durrington (2004)125
4522IL/0036 Europe Pharm. Fund Multicenter
Participants with combined HC, HbA1c <10%, and T2DMRosuvastatin 10Fenofibrate 20053Rosuvastatin 405118149−2.70 (−10.46, 5.06)unclear2No

From: Appendix F, Included Evidence

Cover of Comparative Effectiveness of Lipid-Modifying Agents
Comparative Effectiveness of Lipid-Modifying Agents [Internet].
Comparative Effectiveness Reviews, No. 16.
Sharma M, Ansari MT, Soares-Weiser K, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.